GeoVax Labs, Inc. (GOVX)
GOVXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.1430
-0.0149 (-9.44%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.75m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.1393 to $13.44
- Average volume
- 586.7k
- Previous close
- $0.1579
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $10.00, +6893.0% from here
Earnings
next estimate $-1.02Next report Nov 12, 2026
Mar 2026
-63.8%
Jun 2026
+55.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$6.37m | -$4.44m | -$5.27m | -$4.44m |
| Net income | -$6.32m | -$4.42m | -$5.26m | -$4.43m |
News
8 latest- GeoVax Labs, Inc. Terminates CEO David A. Dodd for Cause on November 5, 2026Fintel · 3 days ago
- GeoVax Labs, Inc. Stockholders Approve Reverse Stock Split and Issuance of Up to 11,395,256 SharesFintel · Oct 27, 2026
- GeoVax Labs, Inc. Enters $1,000,000 Revolving Loan Agreement and Reconstitutes BoardFintel · Oct 27, 2026
- After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data RTTNews · Aug 20, 2026
- GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks · Jun 12, 2026
- Is Co-Diagnostics National Security’s Next Diagnostic Pick?MarketBeat · May 28, 2026
- Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch RTTNews · May 26, 2026
- Biotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalysts RTTNews · May 21, 2026
The company
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax's priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in late 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- geovax.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.